The CEO of ZZ Biotech outlined the design of the phase 2 trial of 3KA-APC, which will enroll 16 patients with amyotrophic lateral sclerosis. [WATCH TIME: 4 minutes]
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights